Ricevi le ultime notizie sulle azioni Aclaris Therapeutics con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di ACRS

Ultime notizie per

ACLARIS THERAPEUTICS INC

Aclaris Therapeutics

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Aclaris Therapeutics, Inc. - Common Stock

Aclaris Therapeutics Inc

News

Health Care

Press Releases

Aclaris Therapeutics to Participate in Two June Healthcare Conferences

Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

General

Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference

Markets

Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes

Management

Aclaris Therapeutics Announces Leadership Transition

Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints

Earnings

Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aclaris Therapeutics to Participate in Two September Healthcare Conferences

Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress

ACRS

Aardvark Therapeutics, Inc. - Common Stock

Aardvark Therapeutics

Aurora Cannabis

ALT5 Sigma

Alto Neuroscience

Atea Pharmaceuticals, Inc. - common stock

Atea Pharmaceuticals

Bioage Labs

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Contineum Therapeutics, Inc. - Common stock

Contineum Therapeutics

Cybin

Journey Medical Corporation - Common Stock

Journey Medical

High Tide

LB Pharmaceuticals

MediWound

Milestone Pharmaceuticals Inc. - Common Shares

Milestone Pharmaceuticals

Neumora Therapeutics, Inc. - Common Stock

Neumora Therapeutics

NeOnc Technologies Holdings, Inc. - Common Stock

NeOnc Technologies Hldgs

Organigram Global

Omeros

Oramed Pharmaceuticals Inc. - Common Stock

Oramed Pharmaceuticals

Cassava Sciences

Scilex Holding

scPharmaceuticals

China SXT Pharmaceuticals, Inc. - Common Stock

China SXT Pharmaceuticals

Tvardi Therapeutics

Ventyx Biosciences

Piper Sandler

HC Wainwright & Co.

Wedbush

Scotiabank

Leerink Partners

Comments

Aclaris Therapeutics Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO